IL17RA
Interleukin-17 receptor A
As of the edition of 20 October 2026, IL17RA (interleukin-17 receptor A, UniProt Q96F46) has 1 drug tested at it and 5 companies on the list, 0 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96F46
- How well studied
- Drug target: an approved drug acts on it
- Solved structures
- 10
- Disease areas
- Skin and connective tissue; Bones, joints and muscles; Immune system; Infections; Lungs and airways; Digestive system; Cancer; Hormones
- Registered trials of its drugs
- 47
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Total | 1 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Brodalumab | Marketed | Phase 4 | Ends 2029 |
1 of 1 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 3 |
| Undetermined | 2 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Kyowa Kirin | Route B |
| Amgen | Route B |
| LEO Pharma | Route B |
The other 2 companies at IL17RA
In the product5 companies in all; 2 are not named here, and no score is.
See the 5 companies at IL17RA, ranked, with the facts behind eachRequest access. Nothing is shown until you do.